We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SEPHIENCE (PTC THERAPEUTICS AUSTRALIA PTY LIMITED)
Product name
SEPHIENCE
Date registered
Evaluation commenced
Decision date
Approval time
195 (255 working days)
Active ingredients
sepiapterin
Registration type
NCE/ NBE
Indication
SEPHIENCE is indicated for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with phenylketonuria (PKU).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.